ConductScience.org, home

Paper40973013

Cardiac hypertrophy at the crossroads: Mechanistic insights and emerging multimodal therapeutic strategies.

Kannan D and 3 others. Eur J Pharmacol, 2025. Cited by 3 papers, by iCite.

Cite this record

ConductScience Library. Cardiac hypertrophy at the crossroads: Mechanistic insights and emerging multimodal therapeutic strategies. Papers, record 40973013. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40973013

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Cardiac hypertrophy at the crossroads: Mechanistic insights and emerging multimodal therapeutic strategies.
PubMed
Journal
Eur J Pharmacol
PubMed
Year
2025
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
3
iCite
Revised in PubMed
2026-10-07
PubMed

Authors4

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Kannan DDharshini
2Rajasingh SSheeja
3Madasamy PParani
4Rajasingh JJohnson

Source PubMed

Download CSV of authors

Topics5

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
CardiomegalyMajor topic
Humans
Animals
Combined Modality Therapy
Genetic Therapy

Grants1

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
R01 HL141345NHLBI NIH HHSUnited StatesR01HL141345PubMed

Source NIH RePORTER

Download CSV of grants

References109

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
118629360Angiotensin II receptor blockers and cardiovascular protection: focus on left ventricular hypertrophy regression and atrial fibrillation prevention.Vasc Health Risk Manag2008https://conductscience.org/library/papers/18629360PubMed
237443814The Microenvironment of the Pathogenesis of Cardiac Hypertrophy.Cells2023https://conductscience.org/library/papers/37443814PubMed
334194329Loganin Inhibits Angiotensin II-Induced Cardiac Hypertrophy Through the JAK2/STAT3 and NF-κB Signaling Pathways.Front Pharmacol2021https://conductscience.org/library/papers/34194329PubMed
418096818Molecular mechanisms of angiotensin II-mediated mitochondrial dysfunction: linking mitochondrial oxidative damage and vascular endothelial dysfunction.Circ Res2008https://conductscience.org/library/papers/18096818PubMed
535642640MicroRNAs as therapeutic targets in cardiovascular disease.J Clin Invest2022https://conductscience.org/library/papers/35642640PubMed
611181961Cytoplasmic signaling pathways that regulate cardiac hypertrophy.Annu Rev Physiol2001https://conductscience.org/library/papers/11181961PubMed
717082763TRPC3 and TRPC6 are essential for angiotensin II-induced cardiac hypertrophy.EMBO J2006https://conductscience.org/library/papers/17082763PubMed
830012983A Novel Class of tRNA-Derived Small Non-Coding RNAs Respond to Myocardial Hypertrophy and Contribute to Intergenerational Inheritance.Biomolecules2018https://conductscience.org/library/papers/30012983PubMed
917973781HMG CoA reductase inhibition and left ventricular mass in hypertrophic cardiomyopathy: a randomized placebo-controlled pilot study.Eur J Clin Invest2007https://conductscience.org/library/papers/17973781PubMed
1032669717Investigation of the safety and feasibility of AAV1/SERCA2a gene transfer in patients with chronic heart failure supported with a left ventricular assist device - the SERCA-LVAD TRIAL.Gene Ther2020https://conductscience.org/library/papers/32669717PubMed
1131982428LncRNA-Mhrt regulates cardiac hypertrophy by modulating the miR-145a-5p/KLF4/myocardin axis.J Mol Cell Cardiol2020https://conductscience.org/library/papers/31982428PubMed
1226683870Concise Review: Review and Perspective of Cell Dosage and Routes of Administration From Preclinical and Clinical Studies of Stem Cell Therapy for Heart Disease.Stem Cells Transl Med2016https://conductscience.org/library/papers/26683870PubMed
1330635403Yes-associated protein (YAP) mediates adaptive cardiac hypertrophy in response to pressure overload.J Biol Chem2019https://conductscience.org/library/papers/30635403PubMed
1431427727Counter-regulatory renin-angiotensin system in cardiovascular disease.Nat Rev Cardiol2020https://conductscience.org/library/papers/31427727PubMed
1527082978Long Non-Coding RNA-ROR Mediates the Reprogramming in Cardiac Hypertrophy.PLoS One2016https://conductscience.org/library/papers/27082978PubMed
1628912181Hypertrophic Cardiomyopathy: Genetics, Pathogenesis, Clinical Manifestations, Diagnosis, and Therapy.Circ Res2017https://conductscience.org/library/papers/28912181PubMed
1722750195Regression of pathological cardiac hypertrophy: signaling pathways and therapeutic targets.Pharmacol Ther2012https://conductscience.org/library/papers/22750195PubMed
1827618650The long noncoding RNA Chaer defines an epigenetic checkpoint in cardiac hypertrophy.Nat Med2016https://conductscience.org/library/papers/27618650PubMed
1930569169Construction and analysis of the lncRNA‑miRNA‑mRNA network based on competitive endogenous RNA reveals functional genes in heart failure.Mol Med Rep2019https://conductscience.org/library/papers/30569169PubMed
2030227820Three Generations of β-blockers: History, Class Differences and Clinical Applicability.Curr Hypertens Rev2019https://conductscience.org/library/papers/30227820PubMed

See all 109 referencesDownload CSV of references

Cited by1

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 3 citations.

PMIDTitleJournalYearIn Papers
42633326Advances in FGF/FGFR Signaling: Implications for Disease and Therapy.MedComm (2020)2026https://conductscience.org/library/papers/42633326

Source PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/40973013

GET https://conductscience.org/api/papers/v1/40973013/references?page=2